Compare CECO & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CECO | VKTX |
|---|---|---|
| Founded | 1966 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Pollution Control Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1B | 4.0B |
| IPO Year | 2002 | 2014 |
| Metric | CECO | VKTX |
|---|---|---|
| Price | $75.39 | $32.13 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | $80.25 | ★ $95.86 |
| AVG Volume (30 Days) | 676.0K | ★ 1.7M |
| Earning Date | 04-28-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 280.56 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $24.84 | N/A |
| Revenue Next Year | $11.51 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $42.85 | $22.96 |
| 52 Week High | $101.24 | $43.15 |
| Indicator | CECO | VKTX |
|---|---|---|
| Relative Strength Index (RSI) | 52.27 | 42.69 |
| Support Level | $74.17 | $31.58 |
| Resistance Level | $83.24 | $32.92 |
| Average True Range (ATR) | 3.46 | 1.37 |
| MACD | 0.83 | -0.05 |
| Stochastic Oscillator | 54.57 | 17.91 |
CECO Environmental Corp is an industrial company, serving industrial air, industrial water, and energy transition markets. It offers various engineered and configured products and solutions, including dampers and diverters, selective catalytic reduction systems, severe-service and industrial cyclones, dust collectors, thermal oxidizers, filtration systems, wet and dry scrubbers, water treatment packages, industrial silencers, etc. These products are offered through brands like Western Airducts, WK, Wakefield Acoustics, Transcend, Verantis, and others. The company's reportable segments are: Engineered Systems, which derive maximum revenue, and Industrial Process Solutions. Geographically, it derives key revenue from the U.S., followed by the Netherlands, the UK, China, and other markets.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.